Get the Stockscreener App
2.00
0.51%
0.02
Ac Immune Sa stock is traded at $2.00, with a volume of 21,274.
It is up +0.51% in the last 24 hours and up +20.97% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$1.98
Open:
$1.97
24h Volume:
21,274
Relative Volume:
0.14
Market Cap:
$220.90M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-2.8189
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
-3.86%
1M Performance:
+20.97%
6M Performance:
-30.18%
1Y Performance:
-48.58%
1-Day Range:
$1.97
$2.05
1-Week Range:
$1.65
$2.1689
52-Week Range:
$1.4299
$4.26
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
1.99 | 220.90M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.93 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.51 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.05 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.20 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.45 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
Handelsbanken Fonder AB Trims Stake in AC Immune SA (NASDAQ:ACIU) - Defense World
AC Immune SA Announces Executive Changes - MarketScreener
AC Immune SA Announces Leadership Changes in Development Team - TipRanks
AC Immune SA (NASDAQ:ACIU) Held Back By Insufficient Growth Even After Shares Climb 31% - simplywall.st
Millennium Management LLC Sells 47,100 Shares of AC Immune SA (NASDAQ:ACIU) - Defense World
Promising Renewable Energy Stocks To Watch Now – June 9th - Defense World
Squarepoint Ops LLC Invests $118,000 in AC Immune SA (NASDAQ:ACIU) - Defense World
June 2025 Penny Stocks With Promising Potential - simplywall.st
Jane Street Group LLC Buys Shares of 24,283 AC Immune SA (NASDAQ:ACIU) - Defense World
Two Sigma Advisers LP Acquires Shares of 13,410 AC Immune SA (NASDAQ:ACIU) - Defense World
ACIUAC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - mx.advfn.com
Northern Trust Corp Makes New Investment in AC Immune SA (NASDAQ:ACIU) - Defense World
Individual investors among AC Immune SA's (NASDAQ:ACIU) largest shareholders, saw gain in holdings value after stock jumped 11% last week - simplywall.st
TRIALS UPDATE: The Latest Alzheimer’s Drug Development News (Q1 2025) - Being Patient
AC Immune SA Announces Board Changes Ahead of June 2025 AGM - TipRanks
Dimensional Fund Advisors LP Has $355,000 Stock Holdings in AC Immune SA (NASDAQ:ACIU) - Defense World
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com - Defense World
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - ADVFN
AC Immune (ACIU) to Release Earnings on Monday - Defense World
AC Immune’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to “Hold” - Defense World
Equities Analysts Issue Forecasts for AC Immune Q2 Earnings - Defense World
FY2027 EPS Estimates for AC Immune Cut by HC Wainwright - Defense World
HC Wainwright Lowers AC Immune (NASDAQ:ACIU) Price Target to $12.00 - Defense World
Planning For Perseverance - Life Science Leader
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates - MSN
AC Immune (ACIU) Stock Rating Maintained, Price Target Lowered | - GuruFocus
H.C. Wainwright cuts AC Immune SA target to $12; maintains buy - Investing.com
AC Immune (ACIU) Target Price Reduced by H.C. Wainwright | ACIU Stock News - GuruFocus
AC Immune price target lowered to $12 from $16 at H.C. Wainwright - TipRanks
AC Immune: Q1 Earnings Snapshot - MySA
AC Immune reports Q1 EPS (19c) vs (18c) last year - TipRanks
AC Immune Reports Q1 2025 Financial Results - TipRanks
ACIU Surpasses Revenue Expectations with Strong Phase 2 Data | A - GuruFocus
AC Immune SA Reports Q1 2025 Financial Results and Clinical Advancements in Neurodegenerative Disease Therapies - Nasdaq
AC Immune Q1 Results: Breakthrough in Parkinson's Treatment Shows Promise, Cash Runway Extended to 2027 - Stock Titan
Precision Prevention: The Latest on Alzheimer’s Vaccines - Being Patient
Renaissance Technologies LLC Has $2 Million Stock Position in AC Immune SA (NASDAQ:ACIU) - American Banking and Market News
Individual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last week - Yahoo Finance
Wells Fargo & Company MN Lowers Stock Holdings in AC Immune SA (NASDAQ:ACIU) - Defense World
Is tau approaching a tipping point in Alzheimer’s drug development? - BioCentury
Q2 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
Q1 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
AC Immune unveils first-in-class Morphomer targeting pathological α-synuclein - BioWorld MedTech
ADPD 2025: Novel treatment modalities in neurodegenerative disorders - BioWorld MedTech
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
5.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):